Chemotherapy of cervix cancer with doxorubicin and cisplatin: A phase I pilot study of the Gynecologic Oncology Group

Twelve women with previously irradiated advanced pelvic cancer were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase 1 study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M² and cisplatin 100 mg/M² every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M². Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.